IC-MPGN
Clinical trials for IC-MPGN explained in plain language.
Never miss a new study
Get alerted when new IC-MPGN trials appear
Sign up with your email to follow new studies for IC-MPGN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could slow rare kidney disease in phase 3 trial
Disease control Recruiting nowThis study tests a drug called iptacopan for people with a rare kidney disease (IC-MPGN). The goal is to see if it can reduce protein in the urine and protect kidney function better than a placebo. About 106 adults and teens will take part, and the study is currently recruiting.
Matched conditions: IC-MPGN
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 08:45 UTC
-
New drug trial aims to control kidney disease in chinese patients
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 30 Chinese adults with kidney diseases caused by the immune system attacking the kidneys (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the drug is safe and can help control the disease, either alone or with another medicat…
Matched conditions: IC-MPGN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug ADX-038 aims to control rare kidney diseases
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system (part of the immune system), including IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have a…
Matched conditions: IC-MPGN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 12, 2026 13:44 UTC